New Zealand’s medicines regulator, Medsafe, approves two psychiatrists to prescribe pharmaceutical-grade MDMA to people with severe post-traumatic stress disorder (PTSD), according to multiple reports. The authorisation allows the clinicians to provide MDMA within their clinics as a treatment option for eligible patients.
Outlets describe the decision as a significant expansion of medical use for MDMA, a substance widely associated with recreational use. The Guardian notes the approval follows Australia’s 2023 authorisation of psychedelics for PTSD and treatment-resistant depression. It also frames New Zealand’s decision as leaving the country among a small number globally to approve MDMA for PTSD.
While all sources agree on Medsafe’s approval and the involvement of two psychiatrists, they differ mainly in emphasis and framing. The Guardian provides broader international context, whereas NZ Herald and NDTV focus primarily on the approval and the use of pharmaceutical-grade MDMA for severe PTSD treatment in New Zealand.
